$INGN
Inogen Inc Stock $ingn

$ingn Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-Q Financial Statement

#000156459020050474 Filed on November 04, 2020

Income Statement

Concept	2020 Q3	2019 Q3
Revenue	$74.33M	$91.76M
YoY Change	-19.0%	-3.7%
Cost Of Revenue	$41.30M	$48.40M
YoY Change	-14.67%	4.09%
Gross Profit	$33.01M	$43.32M
YoY Change	-23.8%	-11.26%
Gross Profit Margin	44.41%	47.2%
Selling, General & Admin	$31.80M	$32.57M
YoY Change	-2.37%	-10.32%
% of Gross Profit	96.35%	75.2%
Research & Development	$3.500M	$2.636M
YoY Change	32.78%	25.76%
% of Gross Profit	10.6%	6.09%
Depreciation & Amortization	$4.710M	$3.670M
YoY Change	28.34%	35.42%
% of Gross Profit	14.27%	8.47%
Operating Expenses	$35.30M	$35.21M
YoY Change	0.26%	-8.35%
Operating Profit	-$2.294M	$8.107M
YoY Change	-128.3%	-22.02%
Interest Expense	$100.0K	$1.100M
YoY Change	-90.91%	22.22%
% of Operating Profit		13.57%
Other Income/Expense, Net	$200.0K	-$503.0K
YoY Change	-139.76%	-155.7%
Pretax Income	-$1.913M	$8.753M
YoY Change	-121.86%	-22.53%
Income Tax	-$214.0K	$1.890M
% Of Pretax Income		21.59%
Net Earnings	-$1.699M	$6.863M
YoY Change	-124.76%	-58.23%
Net Earnings / Revenue	-2.29%	7.48%
Basic Earnings Per Share	-$0.08	$0.31
Diluted Earnings Per Share	-$0.08	$0.31
COMMON SHARES
Basic Shares Outstanding	22.00M	21.84M
Diluted Shares Outstanding	22.00M	22.19M

Balance Sheet

Concept	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$220.5M	$200.6M
YoY Change	9.9%	-10.39%
Cash & Equivalents	$214.0M	$156.1M
Short-Term Investments	$6.525M	$44.51M
Other Short-Term Assets	$18.90M	$11.10M
YoY Change	70.27%	30.59%
Inventory	$29.22M	$34.07M
Prepaid Expenses
Receivables	$31.69M	$41.18M
Other Receivables	$3.100M	$2.800M
Total Short-Term Assets	$303.4M	$289.8M
YoY Change	4.68%	-3.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$25.32M	$19.89M
YoY Change	27.31%	-13.53%
Goodwill	$33.05M	$33.28M
YoY Change	-0.67%	1354.41%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$18.20M	$4.664M
YoY Change	290.22%	-83.46%
Total Long-Term Assets	$156.9M	$154.9M
YoY Change	1.29%	169.38%
TOTAL ASSETS
Total Short-Term Assets	$303.4M	$289.8M
Total Long-Term Assets	$156.9M	$154.9M
Total Assets	$460.3M	$444.7M
YoY Change	3.5%	24.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.514M	$18.47M
YoY Change	-48.49%	40.62%
Accrued Expenses	$20.00M	$11.90M
YoY Change	68.07%	-22.73%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$52.00M	$50.00M
YoY Change	4.0%	8.46%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$55.80M	$51.30M
YoY Change	8.77%	164.43%
Total Long-Term Liabilities	$55.80M	$51.30M
YoY Change	8.77%	164.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$52.00M	$50.00M
Total Long-Term Liabilities	$55.80M	$51.30M
Total Liabilities	$107.8M	$101.6M
YoY Change	6.1%	54.41%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$352.5M	$343.1M
YoY Change
Total Liabilities & Shareholders Equity	$460.3M	$444.7M
YoY Change	3.51%	24.53%

Cashflow Statement

Concept	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	-$1.699M	$6.863M
YoY Change	-124.76%	-58.23%
Depreciation, Depletion And Amortization	$4.710M	$3.670M
YoY Change	28.34%	35.42%
Cash From Operating Activities	$6.750M	$14.60M
YoY Change	-53.77%	1.53%
INVESTING ACTIVITIES
Capital Expenditures	-$6.010M	-$310.0K
YoY Change	1838.71%	-89.84%
Acquisitions
YoY Change
Other Investing Activities	-$1.950M	-$73.37M
YoY Change	-97.34%	1034.0%
Cash From Investing Activities	-$7.970M	-$73.68M
YoY Change	-89.18%	673.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	940.0K	1.330M
YoY Change	-29.32%	-73.45%
NET CHANGE
Cash From Operating Activities	6.750M	14.60M
Cash From Investing Activities	-7.970M	-73.68M
Cash From Financing Activities	940.0K	1.330M
Net Change In Cash	-280.0K	-57.75M
YoY Change	-99.52%	-685.11%
FREE CASH FLOW
Cash From Operating Activities	$6.750M	$14.60M
Capital Expenditures	-$6.010M	-$310.0K
Free Cash Flow	$12.76M	$14.91M
YoY Change	-14.42%	-14.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y1M2D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P2Y1M2D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y1M2D
	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y10M2D
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	158000
CY2019Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1223000
CY2019Q3	ingn	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	6000
CY2019Q3	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	46000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	6863000
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-409000
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	343146000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	351114000
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2050000
CY2020Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	996000
CY2020Q3	ingn	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	3000
CY2020Q3	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	47000
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	89000
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	352500000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	310424000
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2748000
	ingn	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	73000
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	764000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2036000
	us-gaap	Net Income Loss NetIncomeLoss	22325000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-480000
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	343146000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	344621000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6111000
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2084000
	ingn	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	14000
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	274000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	186000
	us-gaap	Net Income Loss NetIncomeLoss	-708000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	494000
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	352500000
	us-gaap	Net Income Loss NetIncomeLoss	22325000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9216000
	ingn	Gain Loss On Write Off Of Rental Units And Other Fixed Assets GainLossOnWriteOffOfRentalUnitsAndOtherFixedAssets	-473000
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	64000
	ingn	Provision For Sales Returns And Doubtful Accounts ProvisionForSalesReturnsAndDoubtfulAccounts	13204000
	ingn	Health Care Organization Patient Service Revenue Adjustments HealthCareOrganizationPatientServiceRevenueAdjustments	1701000
	us-gaap	Inventory Write Down InventoryWriteDown	593000
	us-gaap	Share Based Compensation ShareBasedCompensation	6930000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5908000
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-832000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	31204000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	58681000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	57900000
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	31000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2275000
	ingn	Payments To Produce And Purchase Rental Equipment PaymentsToProduceAndPurchaseRentalEquipment	2187000
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	166000
	ingn	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	3744000
	ingn	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	7317000
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	70401000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-75509000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2036000
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2748000
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	837000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3947000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-145000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-40503000
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	156131000
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	25749000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	18000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition and determining the stand-alone selling price (SSP) of performance obligations, inventory and rental asset valuations and write-downs, accounts receivable allowances for bad debts, returns and adjustments, warranty expense, stock compensation expense, depreciation and amortization, income tax provision and uncertain tax positions, fair value of financial instruments, fair value of acquired intangible assets and goodwill and fair value of earnout liabilities. Actual results could differ from these estimates.</p>
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	31691000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34325000
CY2020Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	33099000
CY2019Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	36104000
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2019Q4	ingn	Doubtful Accounts DoubtfulAccounts	205000
CY2020Q3	ingn	Doubtful Accounts DoubtfulAccounts	114000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	494000
CY2020Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	46137000
CY2020Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	167847000
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	213984000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198037000
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	6525000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11057000
CY2020Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	1659000
CY2019Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	590000
CY2020Q3	ingn	Rental Revenue Adjustments RentalRevenueAdjustments	640000
CY2019Q4	ingn	Rental Revenue Adjustments RentalRevenueAdjustments	411000
CY2020Q3	ingn	Allowances For Sales Returns AllowancesForSalesReturns	654000
CY2019Q4	ingn	Allowances For Sales Returns AllowancesForSalesReturns	1163000
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1408000
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1779000
CY2020Q3	ingn	Percentage Of Non Us Revenue Invoiced In Euros PercentageOfNonUSRevenueInvoicedInEuros	0.834
	ingn	Percentage Of Non Us Revenue Invoiced In Euros PercentageOfNonUSRevenueInvoicedInEuros	0.756
	ingn	Percentage Of Non Us Revenue Invoiced In Euros PercentageOfNonUSRevenueInvoicedInEuros	0.712
CY2020Q3	us-gaap	Revenues Revenues	74329000
CY2019Q3	us-gaap	Revenues Revenues	91761000
	us-gaap	Revenues Revenues	234509000
	us-gaap	Revenues Revenues	283026000
	ingn	Transfer Of Inventory To Rental Equipment TransferOfInventoryToRentalEquipment	1795000
CY2020Q3	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	25566000
CY2020Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4560000
CY2020Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	906000
CY2020Q3	us-gaap	Inventory Net InventoryNet	29220000
CY2019Q4	us-gaap	Inventory Net InventoryNet	35664000
CY2020Q3	us-gaap	Property Plant And Equipment Salvage Value PropertyPlantAndEquipmentSalvageValue	0
	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	1776000
	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	2301000
CY2020Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2457000
CY2019Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2393000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6907000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7295000
CY2020Q3	ingn	Rental Equipment Allowance RentalEquipmentAllowance	345000
CY2019Q4	ingn	Rental Equipment Allowance RentalEquipmentAllowance	395000
CY2020Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	70475000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	64294000
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45155000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	44856000
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25320000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19438000
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2019Q4	us-gaap	Goodwill Goodwill	32954000
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-100000
CY2020Q3	us-gaap	Goodwill Goodwill	33054000
CY2020Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	84473000
CY2020Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13464000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	84282000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6749000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	77533000
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2257000
CY2020Q3	ingn	Finite Lived Intangible Asset Expected Amortization Year One FiniteLivedIntangibleAssetExpectedAmortizationYearOne	8728000
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	8410000
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	7835000
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	7830000
CY2020Q3	ingn	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	35949000
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	71009000
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9514000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	16399000
CY2020Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	8812000
CY2019Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	11124000
CY2020Q3	ingn	Accrued Purchasing Card Liability AccruedPurchasingCardLiability	2323000
CY2019Q4	ingn	Accrued Purchasing Card Liability AccruedPurchasingCardLiability	1675000
CY2020Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	429000
CY2019Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	713000
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8122000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	819000
CY2020Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	29200000
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	30730000
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7234000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6215000
CY2020Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	4000
CY2019Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	87000
CY2020Q3	ingn	Accrued Wages And Other Payroll Related Items Current AccruedWagesAndOtherPayrollRelatedItemsCurrent	4463000
CY2019Q4	ingn	Accrued Wages And Other Payroll Related Items Current AccruedWagesAndOtherPayrollRelatedItemsCurrent	3158000
CY2020Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2620000
CY2019Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2169000
CY2020Q3	ingn	Accrued Employee Stock Purchase Plan Deductions AccruedEmployeeStockPurchasePlanDeductions	147000
CY2019Q4	ingn	Accrued Employee Stock Purchase Plan Deductions AccruedEmployeeStockPurchasePlanDeductions	801000
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	options to extend the leases for up to 5 years.
	us-gaap	Operating Lease Payments OperatingLeasePayments	1803000
	us-gaap	Operating Lease Payments OperatingLeasePayments	1820000
	us-gaap	Operating Lease Cost OperatingLeaseCost	2045000
	us-gaap	Operating Lease Cost OperatingLeaseCost	1703000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5234000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6418000
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2019Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.033
CY2019Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.038
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	2199000
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	1993000
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	1844000
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	1842000
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive	596000
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive	3211000
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11685000
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1225000
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	10460000
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1890000
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8570000
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	10460000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-1699000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	6863000
	us-gaap	Net Income Loss NetIncomeLoss	-708000
	us-gaap	Net Income Loss NetIncomeLoss	22325000
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21998299
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21840473
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21959521
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21802468
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21998299
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22191688
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21959521
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22387146
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.02
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.00
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21998299
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21840473
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21959521
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21802468
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	206274
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	351215
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	252096
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	584678
CY2020Q3	ingn	Weighted Average Number Of Diluted Shares Outstanding Based On Net Loss WeightedAverageNumberOfDilutedSharesOutstandingBasedOnNetLoss	22204573
CY2019Q3	ingn	Weighted Average Number Of Diluted Shares Outstanding Based On Net Loss WeightedAverageNumberOfDilutedSharesOutstandingBasedOnNetLoss	22191688
	ingn	Weighted Average Number Of Diluted Shares Outstanding Based On Net Loss WeightedAverageNumberOfDilutedSharesOutstandingBasedOnNetLoss	22211617
	ingn	Weighted Average Number Of Diluted Shares Outstanding Based On Net Loss WeightedAverageNumberOfDilutedSharesOutstandingBasedOnNetLoss	22387146
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1051348
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	315425
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	691470
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	235002
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	980884
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.24
CY2019	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	34.07
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	9324
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	35.30
CY2020Q3	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Expected To Vest Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExpectedToVestPerShareAverageIntrinsicValue	5.56
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	269000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	7017000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6111000
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2050000
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1565000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6930000
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2050000
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1565000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6111000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6930000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	20.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	6779
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	48.23
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.30
	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	5.56
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	964781
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	35.30
CY2020Q3	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Exercisable Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExercisablePerShareAverageIntrinsicValue	5.56
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	964781
CY2020Q3	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	144000
CY2020Q3	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	457000
CY2020Q3	us-gaap	Contractual Obligation ContractualObligation	601000
CY2020Q3	us-gaap	Purchase Obligation PurchaseObligation	56500000
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	12571000
CY2018Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	9530000
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	7299000
CY2019	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	8131000
	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	-627000
CY2019	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	1433000
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	5316000
CY2019	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	6523000
CY2020Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	13927000
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	12571000
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	3980000
CY2020Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3901000
CY2019Q2	ingn	Number Of Lawsuits NumberOfLawsuits	2
CY2019Q4	ingn	Number Of Additional Shareholder Derivative Who Filed Lawsuits NumberOfAdditionalShareholderDerivativeWhoFiledLawsuits	3
CY2020Q1	ingn	Number Of Consolidated Shareholder Derivative Lawsuits NumberOfConsolidatedShareholderDerivativeLawsuits	4
CY2020Q2	ingn	Number Of Consolidated Shareholder Derivative Lawsuits NumberOfConsolidatedShareholderDerivativeLawsuits	2
CY2020Q3	ingn	Number Of Contract Designated Hedges NumberOfContractDesignatedHedges	19
CY2020Q3	ingn	Number Of Contract Non Designated Hedges NumberOfContractNonDesignatedHedges	1
CY2019Q3	ingn	Number Of Contract Designated Hedges NumberOfContractDesignatedHedges	5
CY2019Q3	ingn	Number Of Contract Non Designated Hedges NumberOfContractNonDesignatedHedges	2

Files In Submission

Name	View Source	Status
0001564590-20-050474-index-headers.html	Edgar Link	pending
0001564590-20-050474-index.html	Edgar Link	pending
0001564590-20-050474.txt	Edgar Link	pending
0001564590-20-050474-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ingn-10q_20200930.htm	Edgar Link	pending
ingn-10q_20200930_htm.xml	Edgar Link	completed
ingn-20200930.xsd	Edgar Link	pending
ingn-20200930_cal.xml	Edgar Link	unprocessable
ingn-20200930_def.xml	Edgar Link	unprocessable
ingn-20200930_lab.xml	Edgar Link	unprocessable
ingn-20200930_pre.xml	Edgar Link	unprocessable
ingn-ex101_64.htm	Edgar Link	pending
ingn-ex311_10.htm	Edgar Link	pending
ingn-ex312_7.htm	Edgar Link	pending
ingn-ex321_8.htm	Edgar Link	pending
ingn-ex322_6.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INGN
Inogen Inc Stock $ingn

2020 Q3 Form 10-Q Financial Statement

#000156459020050474 Filed on November 04, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INGN Inogen Inc Stock $ingn

2020 Q3 Form 10-Q Financial Statement

#000156459020050474 Filed on November 04, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INGN
Inogen Inc Stock $ingn